Does Chemotherapy-Induced Liver Injury Impair Postoperative Outcomes After Laparoscopic Liver Resection for Colorectal Metastases?


Journal

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084

Informations de publication

Date de publication:
05 2021
Historique:
received: 20 01 2020
accepted: 25 04 2020
pubmed: 16 5 2020
medline: 29 5 2021
entrez: 16 5 2020
Statut: ppublish

Résumé

Chemotherapy-associated liver injuries (CALI) have been associated with poor postoperative outcome after open liver resection. To date, no data concerning any correlation of CALI and laparoscopic liver resection (LLR) are available. In the present study, we evaluated the impact of CALI on short-term outcomes in patients undergoing LLR. All patients who underwent in our department LLR for colorectal liver metastases (CRLM) from 2000 to 2016 were retrospectively reviewed. Patients were divided in 4 groups according to their pathological histology. In group 1 patients had normal liver parenchyma. Group 2 included patients with steatosis and steatohepatitis. Patients with sinusoidal obstruction syndrome (SOS) and nodular regenerative hyperplasia (NRH) were allocated to group 3, whereas the remaining with fibrosis and cirrhosis, were assigned to group 4. A total of 490 LLR for CRLM were included in the study. Perioperative details and morbidity did not differ significantly between the four groups. Subgroup analysis showed that NRH was associated with higher amount of blood loss (p = 0.043), overall (p = 0.021) and liver-specific morbidity (p = 0.039). NRH is a severe form of CALI that may worsen the short-term outcomes of patients undergoing LLR for CRLM. However, the remaining forms of CALI do not have a significant impact on perioperative outcomes after LLR.

Sections du résumé

BACKGROUND
Chemotherapy-associated liver injuries (CALI) have been associated with poor postoperative outcome after open liver resection. To date, no data concerning any correlation of CALI and laparoscopic liver resection (LLR) are available. In the present study, we evaluated the impact of CALI on short-term outcomes in patients undergoing LLR.
MATERIALS AND METHODS
All patients who underwent in our department LLR for colorectal liver metastases (CRLM) from 2000 to 2016 were retrospectively reviewed. Patients were divided in 4 groups according to their pathological histology. In group 1 patients had normal liver parenchyma. Group 2 included patients with steatosis and steatohepatitis. Patients with sinusoidal obstruction syndrome (SOS) and nodular regenerative hyperplasia (NRH) were allocated to group 3, whereas the remaining with fibrosis and cirrhosis, were assigned to group 4.
RESULTS
A total of 490 LLR for CRLM were included in the study. Perioperative details and morbidity did not differ significantly between the four groups. Subgroup analysis showed that NRH was associated with higher amount of blood loss (p = 0.043), overall (p = 0.021) and liver-specific morbidity (p = 0.039).
CONCLUSION
NRH is a severe form of CALI that may worsen the short-term outcomes of patients undergoing LLR for CRLM. However, the remaining forms of CALI do not have a significant impact on perioperative outcomes after LLR.

Identifiants

pubmed: 32410180
doi: 10.1007/s11605-020-04636-0
pii: 10.1007/s11605-020-04636-0
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1203-1211

Références

Jones RP, Kokudo N, Folprecht G, et al. Colorectal liver metastases: a critical review of state of the art. Liver Cancer 2017;6(1):66–71.
doi: 10.1159/000449348
McMillan DC, McArdle CS. Epidemiology of colorectal liver metastases. Surg Oncol. 2007;16(1):3–5.
pubmed: 17493802 doi: 10.1016/j.suronc.2007.04.008 pmcid: 17493802
Beamish P, Lemke M, Li J, et al. Validation of clinical risk score for colorectal liver metastases resected in a contemporary multicenter cohort. HPB (Oxford). 2017; 19(8):675-681.
pubmed: 28495435 doi: 10.1016/j.hpb.2017.03.010 pmcid: 28495435
Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy : a model to predict long-term survivam. Ann Surg 2004;240:644-657.
pubmed: 15383792 pmcid: 1356466 doi: 10.1097/01.sla.0000141198.92114.f6
Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109-115.
pubmed: 12559192 doi: 10.1016/S1091-255X(02)00121-X pmcid: 12559192
Viganò L, Capussotti L, De Rosa G, et al. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258(5):731–40.
pubmed: 24045448 doi: 10.1097/SLA.0b013e3182a6183e pmcid: 24045448
Zeiss J, Merrick HW, Savolaine ER, et al. Fatty liver change as a result of hepatic artery infusion chemotherapy. Am J Clin Oncol 1990;13:156-160.
pubmed: 2138409 doi: 10.1097/00000421-199004000-00013 pmcid: 2138409
Peppercorn PD, Reznek RH, Wilson P, et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998;77:2008-2011.
pubmed: 9667683 pmcid: 2150330 doi: 10.1038/bjc.1998.333
Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460–466.
pubmed: 14998849 doi: 10.1093/annonc/mdh095 pmcid: 14998849
Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-2072.
pubmed: 16648507 doi: 10.1200/JCO.2005.05.3074
Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008;247:118-124.
pubmed: 18156931 doi: 10.1097/SLA.0b013e31815774de
Scuderi V, Barkhatov L, Montalti R, et al. Outcome after laparoscopic and open resections of posterosuperior segments of the liver. Br J Surg. 2017; 104(6):751–759.
pubmed: 28194774 doi: 10.1002/bjs.10489
Allard M-A, Cunha AS, Gayet B, et al. Early and long-term oncological outcomes after laparoscopic resection for colorectal liver metastases: a propensity score-based analysis. Ann Surg. 2015; 262(5):794–802.
pubmed: 26583668 doi: 10.1097/SLA.0000000000001475
Fretland AA, Dagenborg VJ, Bjornelv GMW, et al. Laparoscopic versus open resection for colorectal liver metastases. Ann Surg. 2017; 267:199–207.
doi: 10.1097/SLA.0000000000002353
Nomi T, Fuks D, Kawaguchi Y, et al. Laparoscopic major hepatectomy for colorectal liver metastases in elderly patients: a single-center, case-matched study. Surg Endosc. 2015; 29(6):1368–1375.
pubmed: 25149638 doi: 10.1007/s00464-014-3806-1
Nomi T, Fuks D, Kawaguchi Y, et al. Learning curve for laparoscopic major hepatectomy. Br J Surg. 2015; 102(7):796–804.
pubmed: 25873161 doi: 10.1002/bjs.9798
Ishizawa T, Gumbs AA, Kokudo N, et al. Laparoscopic segmentectomy of the liver: from segment I to VIII. Ann Surg. 2012; 256(6):959–964.
pubmed: 22968066 doi: 10.1097/SLA.0b013e31825ffed3
Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240(2):205–213.
pubmed: 15273542 pmcid: 1360123 doi: 10.1097/01.sla.0000133083.54934.ae
Balzan S, Belghiti J, Farges O, et al. The “50–50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005; 242(6):824–829.
pubmed: 16327492 pmcid: 1409891 doi: 10.1097/01.sla.0000189131.90876.9e
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.
pubmed: 15915461 doi: 10.1002/hep.20701
Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990;11(5):787–97.
pubmed: 2189821 doi: 10.1002/hep.1840110512
Bedossa P, Poynard T. METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-93.
pubmed: 8690394 doi: 10.1002/hep.510240201
Neal CP, Nana GR, Jones M, et al. Repeat hepatectomy is independently associated with favorable long-term outcome in patients with colorectal liver metastases. Cancer Med 2017;6(2):331–338.
pubmed: 28101946 pmcid: 5313635 doi: 10.1002/cam4.872
Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240: 1052-1061.
pubmed: 15570210 pmcid: 1356520 doi: 10.1097/01.sla.0000145964.08365.01
Parikh AA, Gentner B, Wu TT, et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003;7:1082-1088.
pubmed: 14675719 doi: 10.1016/j.gassur.2003.08.005
Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56: 430–439.
pubmed: 20459550 doi: 10.1111/j.1365-2559.2010.03511.x
Viganò L, Rubbia-Brandt L, De Rosa G, et al. Nodular regenerative hyperplasia in patients undergoing liver resection for colorectal metastases after chemotherapy: risk factors, preoperative assessment and clinical impact. Ann Surg Oncol 2015; 22: 4149–4157.
pubmed: 25845431 doi: 10.1245/s10434-015-4533-0
Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2009; 16: 137–144.
pubmed: 19093069 doi: 10.1007/s00534-008-0016-z
Pilgrim CH, Satgunaseelan L, Pham A, et al. Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidity. HPB 2012; 14: 333–340.
pubmed: 22487071 pmcid: 3384853 doi: 10.1111/j.1477-2574.2012.00454.x
Viganò L, Ravarino N, Ferrero A, et al. Prospective evaluation of accuracy of liver biopsy findings in the identification of chemotherapyassociated liver injuries. Arch Surg 2012; 147: 1085–1091.
pubmed: 22910896 doi: 10.1001/archsurg.2012.1867 pmcid: 22910896
Komori H, Beppu T, Baba Y, et al. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. Int J Clin Oncol 2010; 15: 263–270.
pubmed: 20238233 doi: 10.1007/s10147-010-0046-9
Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860–868.
pubmed: 17492335 doi: 10.1007/s11605-007-0149-4
Sahajpal A, Vollmer CM, Dixon E, et al. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol 2007; 95: 22–27.
pubmed: 17066435 doi: 10.1002/jso.20632
Kandutsch S, Klinger M, Hacker S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 2008; 34: 1231–1236.
pubmed: 18272318 doi: 10.1016/j.ejso.2008.01.001
Fulco RA, Costa C, Germano MP, et al: Hepatotoxicity of camptothecin derivatives in a primary culture system of rat hepatocytes. J Chemother 2000;12:345-351.
pubmed: 10949985 doi: 10.1179/joc.2000.12.4.345
Fernandez FG, Ritter J, Goodwin JW, et al: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200: 845-853.
pubmed: 15922194 doi: 10.1016/j.jamcollsurg.2005.01.024
Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183–1192.
pubmed: 11266382 doi: 10.1053/gast.2001.23256
Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659–1664.
pubmed: 10553793 doi: 10.1001/jama.282.17.1659 pmcid: 10553793
Yang SQ, Lin HZ, Mandal AK, et al. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001; 34: 694–706.
pubmed: 11584365 doi: 10.1053/jhep.2001.28054
McCormack L, Petrowsky H, Jochum W, et al. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case–control study. Ann Surg 2007; 245: 923–930.
pubmed: 17522518 pmcid: 1876953 doi: 10.1097/01.sla.0000251747.80025.b7
Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003;7:1034-1044.
pubmed: 14675713 doi: 10.1016/j.gassur.2003.09.012 pmcid: 14675713
Morris-Stiff G, White AD, Gomez D, et al. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases. Eur J Surg Oncol. 2014 Aug;40(8):1016-20.
pubmed: 24370284 doi: 10.1016/j.ejso.2013.09.015 pmcid: 24370284
Schiffer E, Frossard JL, Rubbia-Brandt L, et al. Hepatic regeneration is decreased in a rat model of sinusoidal obstruction syndrome. J Surg Oncol 2009; 99: 439–446.
pubmed: 19353590 doi: 10.1002/jso.21276 pmcid: 19353590
Zhao J, van Mierlo KMC, Gómez-Ramírez J, Chemotherapy-Associated Liver Injury (CALI) consortium et al; Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 2017 Jul;104(8):990-1002.
pubmed: 28542731 doi: 10.1002/bjs.10572 pmcid: 28542731
M.J. Overman, D.M. Maru, C. Charnsangavej, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury, J. Clin. Oncol. 2010; 28 (15):2549e2555.
doi: 10.1200/JCO.2009.27.5701
K. Imai, Y. Emi, K.I. Iyama, et al. Study Group of Clinical Cancer ancillary, Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome, Eur. J. Surg. Oncol. 2014;40 (5):559e566.
doi: 10.1016/j.ejso.2013.12.009
D. Takeda, H. Nitta, T. Takahara, et al. Effect of preoperative chemotherapy on postoperative liver regeneration following hepatic resection as estimated by liver volume, World J. Surg. Oncol. 2013; 11:65.
pubmed: 23497123 pmcid: 3621216 doi: 10.1186/1477-7819-11-65
Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg 1982;6: 3–9.
pubmed: 7090393 doi: 10.1007/BF01656368 pmcid: 7090393
Jayaraman S, Khakhar A, Yang H, et al. The association between central venous pressure, pneumoperitoneum, and venous carbon dioxide embolism in laparoscopic hepatectomy, Surgical Endoscopy and Other Interventional Techniques. 2009;23:2369-2373.
pubmed: 19266234 doi: 10.1007/s00464-009-0359-9 pmcid: 19266234
Otsuka Y, Katagiri T, Ishii J, et al. Gas embolism in laparoscopic hepatectomy: what is the optimal pneumoperitoneal pressure for laparoscopic major hepatectomy?, Journal of Hepato-Biliary-Pancreatic Sciences. 2013;20: 137-140.
pubmed: 23001192 doi: 10.1007/s00534-012-0556-0
Kawaguchi Y, Nomi T, Fuks D, et al. Hemorrhage control for laparoscopic hepatectomy: technical details and predictive factors for intraoperative blood loss. Surg Endosc. 2016 Jun;30(6):2543-51.
pubmed: 26310533 doi: 10.1007/s00464-015-4520-3
Stevenson HL, Prats MM, Sasatomi E. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis. BMC Cancer. 2017 Jan 7;17(1):35.
pubmed: 28061766 pmcid: 5219653 doi: 10.1186/s12885-016-2998-2
Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol (Meeting Abstracts) 2007;25. LBA5.

Auteurs

Maud Neuberg (M)

Department of Digestive Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Université Paris Descartes, 42 boulevard Jourdan, 75014, Paris, France.

Ioannis Triantafyllidis (I)

Department of Digestive Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Université Paris Descartes, 42 boulevard Jourdan, 75014, Paris, France.
Department of General Surgery, General Hospital of Veria, Veria, Greece.

Marine Lefevre (M)

Department of Pathology, Institut Mutualiste Montsouris, 42 boulevard Jourdan, 75014, Paris, France.

Mostefa Bennamoun (M)

Department of Oncology, Institut Mutualiste Montsouris, 42 boulevard Jourdan, 75014, Paris, France.

Anthony Sarran (A)

Department of Radiology, Institut Mutualiste Montsouris, 42 boulevard Jourdan, 75014, Paris, France.

Marc Beaussier (M)

Department of Digestive Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Université Paris Descartes, 42 boulevard Jourdan, 75014, Paris, France.

Christophe Louvet (C)

Department of Oncology, Institut Mutualiste Montsouris, 42 boulevard Jourdan, 75014, Paris, France.

Brice Gayet (B)

Department of Digestive Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Université Paris Descartes, 42 boulevard Jourdan, 75014, Paris, France.

David Fuks (D)

Department of Digestive Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Université Paris Descartes, 42 boulevard Jourdan, 75014, Paris, France. david.fuks@imm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH